Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Facilitate 4-AP Compassionate Use INDs For MS, Axelrad Says

Executive Summary

FDA will ensure that multiple sclerosis patients taking 4-aminopyridine will continue to have the unapproved drug available through compassionate use INDs, Associate Director-Policy Jane Axelrad told the Pharmacy Compounding Advisory Committee July 14.
Advertisement

Related Content

Catalyst Stumbles With Filing Of Controversial 'Breakthrough Therapy' Firdapse
In With The Old? 2013 To Mark Rebirth Of CDER’s Pharmacy Compounding, Medical Imaging AdComms
FDA’s Advisory Committee Schedule Hints At Re-formulated Compounding Panel
FDA Advisory Committee Line-Up Shrinks With Elimination Of Two Panels
FDA Advisory Committee Line-Up Shrinks With Elimination Of Two Panels
Advertisement
UsernamePublicRestriction

Register

PS036372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel